Olar demonstrated a statistical interaction between IDH mutation and the mitotic index, suggesting that the impact of cellular proliferation on clinical outcome was dependent on IDH mutation status in patients with gliomas [4]. The gene discussed is IDH2; the disease is central nervous system cancer.